Pilot program to provide cheaper GLP-1 via Medicare stokes shortage fears
Summary
The U.S. government will start a pilot program on July 1 to help some adults aged 65 and older pay only $50 per month for certain GLP-1 drugs. These drugs help with weight loss and diabetes, but are often very expensive. The program will run until 2027 and aims to make these medicines more affordable for seniors with Medicare, though some challenges and concerns remain.Key Facts
- GLP-1 drugs help people lose weight and manage conditions like diabetes.
- Before the program, these drugs could cost over $400 per month.
- The new Medicare GLP-1 Bridge program will reduce the cost to $50 monthly for some seniors aged 65 and older.
- The program covers three drugs: Foundayo, Wegovy, and Zepbound.
- To qualify, seniors must have Medicare Part D and meet certain health conditions, such as a body mass index (BMI) of 35 or higher, but cannot have type 2 diabetes or some other conditions already covered.
- About 5 million Medicare-aged adults were using GLP-1 drugs in late 2025.
- Doctors expect high demand and possible delays in processing drug approvals.
- The program is temporary and set to end in 2027, raising concerns about what happens afterward when people might regain weight.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.